SLC5A1 and myocardial ischemia: While possible differences related to off-target mechanisms and dosages of the medications cannot be ruled out, cardiomyocyte-specific knock-down of SGLT1 in mice reduced infarct size following myocardial ischemia–reperfusion injury in vivo and ex vivo [40].